TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02600130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells
Description: via peripheral intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Longeveron Mesenchymal Stem Cells
Description: via peripheral intravenous infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: via peripheral intravenous infusion
Study: NCT02548962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03058770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor retraining
Description: Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation technique
Description: Subjects will perform guided relaxation by using the Jacobson technique.
Study: NCT02473952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGIV-C
Description: IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00440765

Intervention type: DRUG
Intervention: bortezomib
Description: dose as determined (observational study) by treating physician
Study: NCT00823719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab + ICE
Description: 3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m\^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m\^2 on days 1, 2 and 3 of dosing cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofatumumab + DHAP
Description: 3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m\^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m\^2 q12 hrs (2 doses) on day 2 of dosing cycle.
Study: NCT00965913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: 15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch Comparator
Description: 15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
Study: NCT02726737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sterile distilled water
Study: NCT02366065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
Study: NCT03633019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: high dose rhTPO ih
Study: NCT03264079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl capsules 10 mg
Description: One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsules 100 mg
Description: Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
Study: NCT02883387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative CT angiography
Description: Patients will receive a CT scan to map the blood vessels to be used during surgery for breast reconstruction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Preoperative Imaging
Description: No imaging will be done to map blood vessels prior to surgery
Study: NCT02414854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Study: NCT03669029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg
Description: Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab treatment optimization.
Description: Golimumab dosing will be optimized in patients without clinical response at week 6.
Study: NCT02563912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handbook
Description: Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication chart
Description: Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
Study: NCT04154124

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: whole-body PET/CT scan and pelvic PET/MR scan (MR protocol will include three plane fast spin echo T2 weighted, DWI and dynamic contrast enhanced imaging). The ad interim assessment will use a pelvic PET/MR scan only (without PET/CT), to avoid the radiation associated with whole body CT. In the staging and post-nT assessment, the addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
Study: NCT00649012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone HCl Tablets 45 mg
Description: 45mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos® Tablets 45 mg
Description: 45mg, single dose fed
Study: NCT01847846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask - prototype
Description: prototype mask, wore for all sleeps for 4 and 8 weeks (as randomly selected). Mask to be used in conjunction with participant's usual prescribed CPAP settings.
Study: NCT00546728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: exenatide 10 mcg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 500 twice daily
Study: NCT04066218

Intervention type: OTHER
Intervention: Interviews
Description: * Participation will serve as verbal consent.~* Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~* REDCap link will be sent for PROMIS SexFS Brief.~* PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~* Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool.

Intervention type: OTHER
Intervention: Interviews
Description: * Participation will serve as verbal consent.~* Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~* REDCap link will be sent for PROMIS SexFS Brief.~* PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~* Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool.
Study: NCT03750487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-screening & brief intervention (e-SBI)
Description: Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control e-SBI
Description: Computer-delivered screening and brief motivational intervention targeting healthy eating and exercise
Study: NCT02414854

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed
Study: NCT00830388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% Foam
Description: Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
Study: NCT02260141

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: d-ribose
Description: giving ribose in those with a diagnosis of Alzheimer's and/or dementia
Study: NCT01430104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered subcutaneously during the Treatment Period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspara-CA 600 mg
Description: Administered orally throughout the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfarol 1.0 µg
Description: Administered orally throughout the study
Study: NCT01861119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silicone gel Kelo-cort™;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onion extract gel Contractubex™
Study: NCT00472706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: excision
Description: excision 3 mm margin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: Photodynamic therapy
Study: NCT01440595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir 100 mg tablets once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir 100 mg tablets once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Grazoprevir 100 mg tablets once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Grazoprevir
Description: Placebo to Grazoprevir once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (Peg-IFN)
Description: Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (Peg-IFN)
Description: Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b (Peg-IFN)
Description: Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2b (Peg-IFN)
Description: Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
Study: NCT02508311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Albuterol Extended Release
Description: Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo tablets twice daily for 16 weeks.
Study: NCT02635815

Intervention type: PROCEDURE
Intervention: Upper gastrointestinal endoscopy
Description: Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440

Intervention type: PROCEDURE
Intervention: Upper gastrointestinal endoscopy
Description: Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
Study: NCT02169674

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EngerixB, GlaxoSmithKline Vaccines
Study: NCT01440595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
Study: NCT01572428

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inspection with Narrow-Band Imaging(NBI)
Description: Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inspection with Narrow-Band Imaging(NBI)
Description: Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard White Light
Description: Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
Study: NCT03334916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YMC026
Description: YMC026 20mL TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20mL TID
Study: NCT02606838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Styx Lancing Device
Description: Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
Study: NCT03769623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolimus
Description: 103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Biolimus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Powerline
Description: 103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Powerline
Study: NCT04336215

Intervention type: OTHER
Intervention: Non-Interventional
Description: This non-interventional study poses no additional risks to people with pre-existing conditions.

Intervention type: OTHER
Intervention: Non-Interventional
Description: This non-interventional study poses no additional risks to people with pre-existing conditions.
Study: NCT02696317

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses with HydraLuxe™
Description: Contact lenses worn during Period 1 or 2, as randomized

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses with HydraLuxe™
Description: Contact lenses worn during Period 1 or 2, as randomized

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Contact lenses worn during Period 1 or 2, as randomized
Study: NCT03004638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6012 300 mg
Description: Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Push
Description: Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI6012 IV Push
Description: Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
Study: NCT02060838

Intervention type: PROCEDURE
Intervention: Acute normovolemic hemodilution (ANH)
Description: Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
Study: NCT03486808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IFG stimulation
Description: stimulating left inferior frontal cortex with transcranial direct current stimulation for 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IFG stimulation
Description: stimulating left inferior frontal cortex with transcranial direct current stimulation for 30 minutes
Study: NCT04126733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib administered as oral tablets given every day for 3 weeks of each 28 days treatment cycle (i.e., 3 weeks on, 1 week off)
Study: NCT02696317

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Contact lenses worn during Period 1 or 2, as randomized
Study: NCT03398538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offloading
Description: Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional (outer) Dressing Application
Description: Application of outer a moisture retentive dressing, and a multi-layer compression dressing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional (outer) Dressing Application
Description: Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
Study: NCT04126733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab (Opdivo)
Description: Administered on day 1 of every treatment cycle.
Study: NCT03835975

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal polysaccharide vaccine
Study: NCT03398538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirragen Wound Matrix Dressing
Description: Application of Mirragen to wound site along with standard of care treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibracol Wound Dressing
Description: Application of Fibracol Alginate along with standard of care treatment
Study: NCT00620308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP
Description: One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP
Description: One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose 5% in water (the vehicle)